organization · Reporting owner
COLUMN GROUP III GP, LP
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONSTELLATION PHARMACEUTICALS INCCNST · Entity 137050 | 10% owner | February 17, 2021 | February 19, 2021 |
| NGM BIOPHARMACEUTICALS INCNGM · Entity 11997 | 10% owner | April 05, 2024 | April 08, 2024 |
| Revolution Medicines, Inc.RVMD · Entity 606 | 10% owner | November 16, 2020 | November 18, 2020 |
| Surrozen, Inc./DESRZN · Entity 6092 | 10% owner | January 15, 2026 | January 20, 2026 |
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | 10% owner | February 24, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONSTELLATION PHARMACEUTICALS INC
Report date February 17, 2021 · Filed February 19, 2021
Jointly reported with COLUMN GROUP L P, COLUMN GROUP III, LP, COLUMN GROUP III-A, LP, COLUMN GROUP GP, LP, PONOI CAPITAL, LP, Ponoi Management, LLC, Ponoi Capital II, LP, Ponoi II Management, LLC, Kutzkey Tim
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 99,155 |
Reported balance
After 2021-02-17 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-02-17 · Sale · Disposed 10,000 · Balance 99,155 F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $36.95 to $37.005, inclusive. The David V. and Alena Z. Goeddel 2004 Trust undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: These securities are held directly by The David V. and Alena Z. Goeddel 2004 Trust. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,880,623 |
Reported balance
Holding disclosure · report date 2021-02-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,880,623 F4: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson, and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,574,229 |
Reported balance
Holding disclosure · report date 2021-02-17 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,574,229 F5: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 19,571 |
Reported balance
Holding disclosure · report date 2021-02-17 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 19,571 F6: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Ponoi Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 22,103 |
Reported balance
Holding disclosure · report date 2021-02-17 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 22,103 F7: The securities are directly held by The Column Group III- A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Ponoi Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 50,000 |
Reported balance
Holding disclosure · report date 2021-02-17 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 50,000 F8: These securities are held directly by the Alena Goeddel Irrevocable Trust |
| Common StockSEC Table I · non-derivative | Direct | 2,584,957 |
Reported balance
Holding disclosure · report date 2021-02-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,584,957 F3: These securities are directly held by The Column Group, LP ("TCG LP"). The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $36.95 to $37.005, inclusive. The David V. and Alena Z. Goeddel 2004 Trust undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2: These securities are held directly by The David V. and Alena Z. Goeddel 2004 Trust.
F3: These securities are directly held by The Column Group, LP ("TCG LP"). The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F4: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson, and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares
F5: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F6: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Ponoi Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F7: The securities are directly held by The Column Group III- A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Ponoi Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F8: These securities are held directly by the Alena Goeddel Irrevocable Trust
NGM BIOPHARMACEUTICALS INC
Report date April 05, 2024 · Filed April 08, 2024
Jointly reported with COLUMN GROUP GP, LP, COLUMN GROUP III, LP, COLUMN GROUP III-A, LP, Column Group IV, LP, Column Group IV-A, LP, Column Group IV GP, LP, TCG IV GP, LLC, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 0 |
Reported balance
After 2024-04-05 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-04-05 · Disposition to issuer · Disposed 949,862 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3) F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-04-05 · Disposition to issuer · Disposed 2,650,177 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2024-04-05 · Disposition to issuer · Disposed 90,442 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2024-04-05 · Disposition to issuer · Disposed 858,035 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2024-04-05 · Disposition to issuer · Disposed 968,990 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2024-04-05 · Disposition to issuer · Disposed 2,265,758 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 11
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 11 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 12
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 12 · 2024-04-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F15: The securities were owned solely by Tim Kutzkey. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 13
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 13 · 2024-04-05 · Disposition to issuer · Disposed 44,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F16: The securities were directly held by Peter Svennilson. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,000 |
Reported balance
After 2024-04-05 transaction · row 14
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 14 · 2024-04-05 · Other · Acquired 1,000 · Balance 1,000 F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2024-04-05 · Disposition to issuer · Disposed 11,103,333 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)
F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.
F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3)
F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F15: The securities were owned solely by Tim Kutzkey.
F16: The securities were directly held by Peter Svennilson.
F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.
Revolution Medicines, Inc.
Report date November 16, 2020 · Filed November 18, 2020
Jointly reported with COLUMN GROUP III, LP, COLUMN GROUP III-A, LP, PONOI CAPITAL, LP, Ponoi Capital II, LP, Ponoi Management, LLC, Ponoi II Management, LLC, Kutzkey Tim, GOEDDEL DAVID V
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,151,026 |
Reported balance
After 2020-11-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-11-16 · Sale · Disposed 952,023 · Balance 2,151,026 F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson, a member of the Issuer's board of directors, and Tim Kutzkey (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,429,180 |
Reported balance
After 2020-11-16 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2020-11-16 · Sale · Disposed 1,075,133 · Balance 2,429,180 F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 685,011 |
Reported balance
Holding disclosure · report date 2020-11-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 685,011 F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 685,011 |
Reported balance
Holding disclosure · report date 2020-11-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 685,011 F4: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson, a member of the Issuer's board of directors, and Tim Kutzkey (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares
F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares
F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares
F4: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Surrozen, Inc./DE
Report date January 15, 2026 · Filed January 20, 2026
Jointly reported with COLUMN GROUP III-A, LP, COLUMN GROUP III, LP, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Svennilson Peter
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Column Group III, LP | 900,292 |
Last balance in matching sequence
After 2026-01-20 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-01-15 · Purchase · Acquired 5,590 · Balance 890,604 F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Row 3 · 2026-01-16 · Purchase · Acquired 1,204 · Balance 891,808 F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Row 5 · 2026-01-20 · Purchase · Acquired 8,484 · Balance 900,292 F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectBy The Column Group III-A, LP | 1,016,658 |
Last balance in matching sequence
After 2026-01-20 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2026-01-15 · Purchase · Acquired 6,303 · Balance 1,005,732 F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Row 4 · 2026-01-16 · Purchase · Acquired 1,358 · Balance 1,007,090 F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Row 6 · 2026-01-20 · Purchase · Acquired 9,568 · Balance 1,016,658 F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectBy The Column Group Opportunity III, LP | 344,827 |
Reported balance
Holding disclosure · report date 2026-01-15 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 344,827 F3: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Managing Partners. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F3: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Managing Partners. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Tenaya Therapeutics, Inc.
Report date February 24, 2026 · Filed February 26, 2026
Jointly reported with COLUMN GROUP III, LP, COLUMN GROUP III-A, LP, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Kutzkey Tim, Svennilson Peter
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,649,281 |
Reported balance
After 2026-02-24 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-02-24 · Sale · Disposed 309,228 · Balance 1,649,281 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,862,545 |
Reported balance
After 2026-02-24 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-02-24 · Sale · Disposed 349,212 · Balance 1,862,545 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-25 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2026-02-25 · Sale · Disposed 1,649,281 · Balance 0 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-25 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2026-02-25 · Sale · Disposed 1,862,545 · Balance 0 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 49,313,559 |
Reported balance
Holding disclosure · report date 2026-02-24 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 49,313,559 F5: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F2: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F3: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F5: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2026 Filed Feb 26, 2026 16:23 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 1,862,545 | $0.56 | $1,047,495.31 |
DisclosureSEC source: 0001193125-26-076814 · ownership.xml · nonDerivative · entry 4 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 16:23 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 1,649,281 | $0.56 | $927,555.63 |
DisclosureSEC source: 0001193125-26-076814 · ownership.xml · nonDerivative · entry 3 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 16:23 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 349,212 | $0.62 | $214,870.14 |
DisclosureSEC source: 0001193125-26-076814 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,862,545 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 16:23 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 309,228 | $0.62 | $190,267.99 |
DisclosureSEC source: 0001193125-26-076814 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,649,281 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 16:13 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 162,291 | $0.60 | $96,920.19 |
DisclosureSEC source: 0001193125-26-067007 · ownership.xml · nonDerivative · entry 4 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,211,757 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.573 to $0.6225, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 16:13 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 143,709 | $0.60 | $85,823.01 |
DisclosureSEC source: 0001193125-26-067007 · ownership.xml · nonDerivative · entry 3 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,958,509 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.573 to $0.6225, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 16:13 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 277,769 | $0.61 | $170,800.16 |
DisclosureSEC source: 0001193125-26-067007 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,374,048 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.60 to $0.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 16:13 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 245,965 | $0.61 | $151,243.88 |
DisclosureSEC source: 0001193125-26-067007 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,102,218 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.60 to $0.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 17:19 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 2,151,458 | $0.68 | $1,464,712.61 |
DisclosureSEC source: 0001193125-26-049028 · ownership.xml · nonDerivative · entry 4 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,651,817 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.65 to $0.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 17:19 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 1,905,115 | $0.68 | $1,297,002.29 |
DisclosureSEC source: 0001193125-26-049028 · ownership.xml · nonDerivative · entry 3 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,348,183 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.65 to $0.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 17:19 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 182,295 | $0.82 | $148,770.95 |
DisclosureSEC source: 0001193125-26-049028 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,803,275 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 17:19 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 161,422 | $0.82 | $131,736.49 |
DisclosureSEC source: 0001193125-26-049028 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,253,298 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 19:35 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 9,568 | $19.60 | $187,531.84 |
DisclosureSEC source: 0001193125-26-016991 · ownership.xml · nonDerivative · entry 6 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 1,016,658 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 19:35 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 8,484 | $19.60 | $166,285.55 |
DisclosureSEC source: 0001193125-26-016991 · ownership.xml · nonDerivative · entry 5 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 900,292 F1 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 19:35 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 1,358 | $20.00 | $27,160.00 |
DisclosureSEC source: 0001193125-26-016991 · ownership.xml · nonDerivative · entry 4 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 1,007,090 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 19:35 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 1,204 | $20.00 | $24,080.00 |
DisclosureSEC source: 0001193125-26-016991 · ownership.xml · nonDerivative · entry 3 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 891,808 F1 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 19:35 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 6,303 | $19.89 | $125,360.37 |
DisclosureSEC source: 0001193125-26-016991 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 1,005,732 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 19:35 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 5,590 | $19.89 | $111,179.51 |
DisclosureSEC source: 0001193125-26-016991 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 890,604 F1 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 14, 2026 Filed Jan 15, 2026 16:10 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 2,927 | $19.99 | $58,505.75 |
DisclosureSEC source: 0001193125-26-014100 · ownership.xml · nonDerivative · entry 4 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 999,429 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 14, 2026 Filed Jan 15, 2026 16:10 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 2,596 | $19.99 | $51,889.63 |
DisclosureSEC source: 0001193125-26-014100 · ownership.xml · nonDerivative · entry 3 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 885,014 F1 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 16:10 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 6,609 | $19.80 | $130,885.30 |
DisclosureSEC source: 0001193125-26-014100 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 996,502 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 16:10 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 5,861 | $19.80 | $116,071.83 |
DisclosureSEC source: 0001193125-26-014100 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 882,418 F1 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 17:23 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 8,003 | $19.89 | $159,157.26 |
DisclosureSEC source: 0001193125-26-007857 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 989,893 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 17:23 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 7,097 | $19.89 | $141,139.46 |
DisclosureSEC source: 0001193125-26-007857 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 876,557 F1 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 17:04 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 16,381 | $19.54 | $320,099.48 |
DisclosureSEC source: 0001193125-25-311384 · ownership.xml · nonDerivative · entry 4 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 981,890 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 17:04 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 14,503 | $19.54 | $283,401.67 |
DisclosureSEC source: 0001193125-25-311384 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 869,460 F1 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| December 04, 2025 Filed Dec 8, 2025 17:04 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 2,791 | $17.35 | $48,415.48 |
DisclosureSEC source: 0001193125-25-311384 · ownership.xml · nonDerivative · entry 3 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 965,509 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| December 04, 2025 Filed Dec 8, 2025 17:04 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 2,475 | $17.35 | $42,933.83 |
DisclosureSEC source: 0001193125-25-311384 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 854,957 F1 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 19:15 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 167,307 | $12.65 | $2,116,433.55 |
DisclosureSEC source: 0001193125-25-284943 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 962,718 F2 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 19:15 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 148,150 | $12.65 | $1,874,097.50 |
DisclosureSEC source: 0001193125-25-284943 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 852,482 F1 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseSecond Tranche Units (Right to Buy) · Derivative | 517,241 | Not disclosed Strike: $11.60 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 21 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group Opportunity II, LP Disclosed balance after: 517,241 Underlying: Common Stock · 775,861 shares Expires not disclosed F11 · security: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · security: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F11 · price: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · price: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F11 · derivative.exercise_date: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · derivative.exercise_date: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F11 · derivative.expiration_date: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · derivative.expiration_date: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F15 · derivative.underlying_shares: Consists of (a) 517,241 shares of the Issuer's Common Stock and (b) 258,620 Series E Warrants to purchase shares of the Issuer's Common Stock. F5 · ownership.nature: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Members"). TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseSecond Tranche Units (Right to Buy) · Derivative | 548,653 | Not disclosed Strike: $11.60 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 20 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 548,653 Underlying: Common Stock · 822,980 shares Expires not disclosed F11 · security: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · security: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F11 · price: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · price: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F11 · derivative.exercise_date: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · derivative.exercise_date: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F11 · derivative.expiration_date: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · derivative.expiration_date: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F14 · derivative.underlying_shares: Consists of (a) 548,653 shares of the Issuer's Common Stock and (b) 274,327 Series E Warrants to purchase shares of the Issuer's Common Stock. F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseSecond Tranche Units (Right to Buy) · Derivative | 485,830 | Not disclosed Strike: $11.60 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 19 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 485,830 Underlying: Common Stock · 728,745 shares Expires not disclosed F11 · security: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · security: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F11 · price: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · price: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F11 · derivative.exercise_date: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · derivative.exercise_date: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F11 · derivative.expiration_date: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · derivative.expiration_date: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F13 · derivative.underlying_shares: Consists of (a) 485,830 shares of the Issuer's Common Stock and (b) 242,915 Series E Warrants to purchase shares of the Issuer's Common Stock. F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseSeries E Common Warrants · Derivative | 172,414 | Not disclosed Strike: $11.54 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 18 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group Opportunity II, LP Disclosed balance after: 172,414 Underlying: Common Stock · 172,414 shares Expires not disclosed F1 · price: Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP"), The Column Group III-A, LP ("TCG III-A LP") and The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased in the Issuer's private placement on March 24, 2025 (the "2025 Private Placement"). F10 · derivative.exercise_date: These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations). F10 · derivative.expiration_date: These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations). F5 · ownership.nature: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Members"). TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseSeries E Common Warrants · Derivative | 182,884 | Not disclosed Strike: $11.54 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 17 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 182,884 Underlying: Common Stock · 182,884 shares Expires not disclosed F1 · price: Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP"), The Column Group III-A, LP ("TCG III-A LP") and The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased in the Issuer's private placement on March 24, 2025 (the "2025 Private Placement"). F10 · derivative.exercise_date: These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations). F10 · derivative.expiration_date: These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations). F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseSeries E Common Warrants · Derivative | 161,943 | Not disclosed Strike: $11.54 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 16 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 161,943 Underlying: Common Stock · 161,943 shares Expires not disclosed F1 · price: Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP"), The Column Group III-A, LP ("TCG III-A LP") and The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased in the Issuer's private placement on March 24, 2025 (the "2025 Private Placement"). F10 · derivative.exercise_date: These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations). F10 · derivative.expiration_date: These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations). F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | OtherSeries D Common Warrants · Derivative | 397,773 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 15 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 0 Underlying: Common Stock · 397,773 shares Expires not disclosed F9 · kind: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement. F7 · price: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · price: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F9 · derivative.exercise_date: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement. F9 · derivative.expiration_date: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement. F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | OtherSeries D Common Warrants · Derivative | 352,225 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 14 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 0 Underlying: Common Stock · 352,225 shares Expires not disclosed F9 · kind: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement. F7 · price: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · price: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F9 · derivative.exercise_date: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement. F9 · derivative.expiration_date: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement. F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | OtherSeries C Common Warrants · Derivative | 397,773 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 13 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 0 Underlying: Common Stock · 397,773 shares Expires not disclosed F9 · kind: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement. F7 · price: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · price: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F9 · derivative.exercise_date: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement. F9 · derivative.expiration_date: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement. F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | OtherSeries C Common Warrants · Derivative | 352,225 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 12 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 0 Underlying: Common Stock · 352,225 shares Expires not disclosed F9 · kind: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement. F9 · price: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement. F9 · derivative.exercise_date: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement. F9 · derivative.expiration_date: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement. F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseSeries B Common Warrants · Derivative | 111,656 | Not disclosed Strike: $11.54 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 11 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 111,656 Underlying: Common Stock · 111,656 shares Expires not disclosed F7 · kind: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · kind: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F7 · price: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · price: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F7 · derivative.exercise_date: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · derivative.exercise_date: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F7 · derivative.expiration_date: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · derivative.expiration_date: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | OtherSeries B Common Warrants · Derivative | 111,656 | Not disclosed Strike: $14.25 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 10 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 0 Underlying: Common Stock · 111,656 shares Expires not disclosed F7 · kind: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · kind: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F7 · price: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · price: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F7 · derivative.exercise_date: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · derivative.exercise_date: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F7 · derivative.expiration_date: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · derivative.expiration_date: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseSeries B Common Warrants · Derivative | 98,870 | Not disclosed Strike: $11.54 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 9 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 98,870 Underlying: Common Stock · 98,870 shares Expires not disclosed F7 · kind: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · kind: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F7 · price: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · price: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F7 · derivative.exercise_date: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · derivative.exercise_date: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F7 · derivative.expiration_date: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · derivative.expiration_date: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | OtherSeries B Common Warrants · Derivative | 98,870 | Not disclosed Strike: $14.25 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 8 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 0 Underlying: Common Stock · 98,870 shares Expires not disclosed F7 · kind: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · kind: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F7 · price: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · price: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F7 · derivative.exercise_date: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · derivative.exercise_date: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F7 · derivative.expiration_date: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, F8 · derivative.expiration_date: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseSeries A Common Warrants · Derivative | 102,651 | Not disclosed Strike: $11.54 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 7 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 102,651 Underlying: Common Stock · 102,651 shares Expires not disclosed F6 · kind: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F6 · price: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F6 · derivative.exercise_date: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F6 · derivative.expiration_date: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | OtherSeries A Common Warrants · Derivative | 102,651 | Not disclosed Strike: $15.50 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 6 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 0 Underlying: Common Stock · 102,651 shares Expires not disclosed F6 · kind: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F6 · price: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F6 · derivative.exercise_date: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F6 · derivative.expiration_date: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseSeries A Common Warrants · Derivative | 90,897 | Not disclosed Strike: $11.54 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 5 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 90,897 Underlying: Common Stock · 90,897 shares Expires not disclosed F6 · kind: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F6 · price: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F6 · derivative.exercise_date: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F6 · derivative.expiration_date: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | OtherSeries A Common Warrants · Derivative | 90,897 | Not disclosed Strike: $15.50 | Not disclosed |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 4 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 0 Underlying: Common Stock · 90,897 shares Expires not disclosed F6 · kind: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F6 · price: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F6 · derivative.exercise_date: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F6 · derivative.expiration_date: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 344,827 | $11.60 | $3,999,993.20 |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · nonDerivative · entry 3 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group Opportunity III, LP Disclosed balance after: 344,827 F1 · price: Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP"), The Column Group III-A, LP ("TCG III-A LP") and The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased in the Issuer's private placement on March 24, 2025 (the "2025 Private Placement"). F5 · ownership.nature: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Members"). TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | PurchaseCommon Stock | 365,769 | $11.60 | $4,242,920.40 |
DisclosureSEC source: 0000950170-25-047104 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 795,411 F1 · price: Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP"), The Column Group III-A, LP ("TCG III-A LP") and The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased in the Issuer's private placement on March 24, 2025 (the "2025 Private Placement"). F2 · balance_after: The amount beneficially owned by the Reporting Persons, has been updated to correct an administrative error in previously reported Form 4s. F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.